The emerging role of medical affairs within the modern pharmaceutical company

被引:0
作者
Wolin, MJ [1 ]
Ayers, PM [1 ]
Chan, EK [1 ]
机构
[1] Chiron Corp, Dept Med Affairs, Emeryville, CA 94608 USA
来源
DRUG INFORMATION JOURNAL | 2001年 / 35卷 / 02期
关键词
medical affairs; drug development; regulations; medical science liaison;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Medical affairs groups are an increasingly vital part of the modem pharmaceutical company. This review will highlight the major functions, customary organizational structure, and responsibilities of medical affairs departments. These groups perform a wide range of activities often overlapping with sales, marketing, clinical development, and customer service. Medical affairs personnel must strive for the highest scientific integrity in order to produce successful clinical trials and provide the greatest support for the market. It is important that they well understand the regulations surrounding their activities and appreciate the commercial implications of their work. How well the medical affairs group maintains this delicate balance will determine its overall success.
引用
收藏
页码:547 / 555
页数:9
相关论文
共 36 条
[1]  
Alberts DS, 1999, SEMIN ONCOL, V26, P8
[2]  
Amadori D, 1996, SEMIN ONCOL, V23, P16
[3]   Second malignancies in patients with hairy cell leukemia in British Columbia: A 20-year experience [J].
Au, WY ;
Klasa, RJ ;
Gallagher, R ;
Le, N ;
Gascoyne, RD ;
Connors, JM .
BLOOD, 1998, 92 (04) :1160-1164
[4]   MAINTENANCE THERAPY WITH INTERFERON ALFA-2B IN PATIENTS WITH DIFFUSE LARGE CELL LYMPHOMA [J].
AVILES, A ;
DIAZMAQUEO, JC ;
GARCIA, EL ;
TALAVERA, A ;
GUZMAN, R .
INVESTIGATIONAL NEW DRUGS, 1992, 10 (04) :351-355
[5]   TREATMENT OF REFRACTORY LOW-GRADE LYMPHOMA WITH CHLORAMBUCIL ALTERNATING WITH INTERFERON AND RADIOTHERAPY [J].
AVILES, A ;
TALAVERA, A ;
GUZMAN, R ;
CUADRA, I .
CANCER BIOTHERAPY, 1995, 10 (04) :273-277
[6]   Phase I study of Doxil and vinorelbine in metastatic breast cancer [J].
Burstein, HJ ;
Ramirez, MJ ;
Petros, WP ;
Clarke, KD ;
Warmuth, MA ;
Marcom, PK ;
Matulonis, UA ;
Parker, LM ;
Harris, LN ;
Winer, EP .
ANNALS OF ONCOLOGY, 1999, 10 (09) :1113-1116
[7]  
CALDAS C, 1993, SEMIN ONCOL, V20, P50
[8]  
CAROSI G, 1992, Pharmacological Research, V26, P58, DOI 10.1016/1043-6618(92)90598-6
[9]   Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma:: An aid to clinical decision making [J].
Cole, BF ;
Solal-Céligny, P ;
Gelber, RD ;
Lepage, E ;
Gisselbrecht, C ;
Reyes, F ;
Sebban, C ;
Sugano, D ;
Tendler, C ;
Goldhirsch, A .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (07) :2339-2344
[10]   RANDOMIZED, SURGICAL ADJUVANT CLINICAL-TRIAL OF RECOMBINANT INTERFERON ALFA-2A IN SELECTED PATIENTS WITH MALIGNANT-MELANOMA [J].
CREAGAN, ET ;
DALTON, RJ ;
AHMANN, DL ;
JUNG, SH ;
MORTON, RF ;
LANGDON, RM ;
KUGLER, J ;
RODRIGUE, LJ .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (11) :2776-2783